paediatric patients starting on renal replacement therapy (RRT) between 2002 and 2007 under the age of 18 years. Estimated glomerular filtration rate (eGFR) was calculated using the Schwartz formula. Data were adjusted for age, gender, treatment modality at start, primary cause of renal failure (PRD) and regions in Europe (eGFR adj ). Results. Median eGFR in the 938 patients starting RRTwas 10.4 mL/min/1.73 m 2 (5th and 95th percentile: 4.0-26.9). Twenty-six patients (2.8%), mainly infants with Finnishtype nephropathy, started with eGFR levels >50 mL/min/ 1.73 m 2 . Younger age, female gender, starting on dialysis and having a short time between the first visit to a paediatric nephrologist (PN) and start of RRT were associated with lower eGFR at start of RRT. Gender differences were only
Introduction
Determining the optimal time to start renal replacement therapy (RRT) is a complex issue, and the decision of when to start RRT in children and adults is based on many factors including clinical, social and laboratory parameters such as the glomerular filtration rate (GFR) [1, 2] . GFR can be measured by taking the average of creatinine and urea clearance in a 24-h urine collection, or estimated (eGFR) based on serum creatinine values using a formula, such as the Schwartz formula, which has been specially developed for children [3, 4] . For a long time, initiation of RRT was based on personal experience of the paediatric nephrologist (PN) [5] . In 2001, an ad hoc European committee for elective peritoneal dialysis (PD) in children stated that dialysis should be initiated when the measured or estimated GFR was between 15 and 10 mL/ min/1.73 m 2 [2] . In 2006, the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines regarding initiation of dialysis in children stated that RRT should be considered when the eGFR falls <14 mL/min/1.73 m 2 and should be recommended when the eGFR falls <8 mL/min/1.73 m 2 [1, 2] . Currently, it is unclear how many patients are treated according to these guidelines in Europe.
The European Society of Paediatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry is a new large collaborative registry that receives population-based data on paediatric patients on RRT from 30 countries [6] . The current paper will focus on the eGFR at the start of RRT. We aimed to (i) study current practice in Europe, (ii) determine how many patients were treated according to the guidelines, (iii) identify factors that determine eGFR at start and (iv) investigate the rate of decline in renal function in the period prior to the start of RRT.
Materials and methods
Within the framework of the ESPN/ERA-EDTA Registry, data were collected from Belgium (till 2005), Czech Republic, Estonia, Finland, France (from 2004 onwards), FYR of Macedonia, Italy (only dialysis patients), Lithuania, the Netherlands (from 2006 onwards), Portugal, Serbia, Slovakia, Slovenia and the UK. All countries collected individual patient data on date of birth, sex, treatment modality at start and changes in treatment [7] . Incident patients aged ≤17 years who started RRT between 2002 and the end of 2007 were included in the current analysis. Information regarding eGFR at the first visit to a PN was available for patients from the Czech Republic, Lithuania, FYR of Macedonia, Portugal, Slovakia and the UK.
Serum creatinine levels were determined according to local practice, and eGFR (mL/min/1.73 m 2 ) was calculated centrally using the Schwartz formula via K × height/serum creatinine (mg/dL) [3] . The K values were 0.45 for those aged ≤1 year, 0.55 for those aged 2-12 years and females aged 13-17 years, and 0.70 for males aged between 13 and 17 years. For a sensitivity analysis for the effect of age, the Counahan formula [8] (K = 0.43 for all patients) and the new abbreviated Schwartz formula [9] (K = 0.41 for all patients) were used, and when analysing the differences between genders in the adolescent age group, a K value of 0.55 was used for both genders.
The cause of renal disease (PRD) was divided into eight groups according to the ERA-EDTA coding system adapted for children [10] . Countries were divided into four regions based on the United Nations classification [11] , namely Nordic countries (Estonia, Finland, Lithuania, UK), Western countries (Belgium, France, the Netherlands), Eastern countries (Czech Republic, Slovakia) and Southern countries (FYR of Macedonia, Italy, Portugal, Serbia, Slovenia).
Analyses
Differences between patients on whom information on eGFR at start was or was not available were calculated by chi-square methods. To test for differences in proportions, the z test was used, while linear regression analysis was used for studying differences in eGFR levels. Fig. 1. eGFR at start for different age groups, gender and treatment modality at start of RRT. median eGFR and its 95% confidence limits (95% CI), eGFR was logtransformed to obtain a normal distribution of eGFR. Associations were adjusted for age, gender, region, PRD group and treatment modality at start (eGFR adj ). When studying eGFR at first visit or the time between the first visit to a PN and start of RRT, data were adjusted for age at first visit, gender, PRD and region. The adjusted eGFRs were recalculated using the distribution of all cases. All analyses were performed in SAS 9.1.
Results

Patient characteristics
A total of 938 patients had information on eGFR levels at the start of RRT. This was 53.9% of the incident RRT population <18 years of age in the participating countries. Table 1 shows the characteristics of the patients. Most patients were male, 17% were <2 years of age while 33% were adolescent (aged 13-17 years). Over half started with PD and 8% started with a pre-emptive transplant. Patients without information on eGFR at start of RRT, the non-participants, had a similar age and gender distribution, but started significantly more often with a transplant and included more patients with an unknown PRD. These differences may have been caused by varying completeness of the data between the different countries.
Median eGFR at start
Median eGFR was 10.4 mL/min/1.73 m 2 at the start of RRT and had a wide range (5th percentile 4.0 and 95th percentile 26.9 mL/min/1.73 m 2 ). Compared with the recommendations from the KDOQI guidelines, 33% had an eGFR <8 mL/min/1.73 m 2 , while 24% seemed to start early compared with the guidelines as they had eGFR levels >14 mL/min/1.73 m 2 (see Table 2 ). Compared with the European guidelines, nearly 50% of the patients started with eGFR levels <10 mL/min/1.73 m 2 , while 33% started RRT with eGFR levels between 10 and 15 mL/min/1.73 m 2 . Figure 1 shows the distribution of the patients starting with various eGFR levels for different subgroups. No trend over time was found for the different years.
Sixty-four (6.8%) patients started with eGFR levels >25 mL/min/1.73 m 2 , and 26 (2.8%) even started with eGFR levels of >50 mL/min/1.73 m 2 . All patients in this latter group had had a bilateral nephrectomy just before start of RRT. Most of them (21 out of 26) were infants and suffered from hereditary nephropathy. These 26 patients were excluded from further analyses.
Determinants of eGFR at initiation of RRT Age. Table 3 shows determinants of eGFR at the start of RRT, adjusted for possible confounders. There was a positive association between age and eGFR at the start of RRT. The <2-year-olds started with 40% lower eGFR adj levels compared with children aged 2-12 years. Adolescents started with nearly double the eGFR adj level compared with infants, and this was significantly higher than the eGFR levels of all other age groups. Data were adjusted for type of treatment, gender, region and PRD. Further adjustment for time between the first visit to a PN and start of RRT did not change the effect. When we applied the Counahan or the new Schwartz formula, using the same K value for all age groups, differences between age groups remained significant although absolute eGFR levels were smaller.
Gender. Females started with slightly but significantly lower eGFR compared with males. This difference between genders was not present in patients <12 years of age but only during adolescent age. It could not be explained by the PRD or treatment modality at start and was present in all regions in Europe. When applying the same K value in males and females, differences in eGFR levels between genders disappeared.
Other factors. The median eGFR differed for the various modalities at start of RRT. Patients who started with a preemptive transplant had 3.4 mL/min/1.73 m 2 higher median eGFR adj compared with those starting on dialysis. There was no difference between the two forms of dialysis treatment, nor between patients receiving a kidney from a living or a deceased donor. Differences between treatment modalities remained after adjustment for time between first visit to a PN and start of RRT, and were consistent over the various age groups.
PRD hardly affected eGFR adj at the start except for patients with hereditary nephropathy or haemolytic-uraemic syndrome (HUS) as these patients had slightly higher eG-FR adj levels at the start of RRT. Those with an unknown PRD had lower eGFR levels compared with patients with a known PRD.
Finally, patients from Eastern Europe had slightly higher eGFR levels at start of RRT compared with the other regions.
First visit to a PN
Of all patients, 35% had information on the first visit to a PN (see Table 1 ). Patients with information were very similar with respect to age and gender, but had slightly different PRDs from those without information on their first visit to the PN. At the first visit, median eGFR was 14.8 mL/min/ 1.73 m 2 with, again, a very wide range (5th percentile 4.3, 95th percentile 100.3 mL/min/1.73 m 2 ). Forty-one percent of the patients had an eGFR >20 mL/min/1.73 m 2 at the first visit.
The median time between the first visit to a PN and start of RRT was 11.3 months. Thirty-one percent of the patients started RRT within a month after the first visit to a PN. Figure 2 shows the relationship of time between the first visit to a PN and start of RRT and the eGFR adj at start of RRT. Patients who started treatment within a month after their first visit had an eGFR adj of 7.5 mL/min/1.73 m 2 at start of RRT, while it was around 12 mL/min/1.73 m 2 for those starting after being under the supervision of a PN for at least 12 months. This relationship remained after adjustment for age, gender, region and PRD.
Decline in renal function
At the first visit to a PN, there were major differences between eGFR levels for the different PRDs (Figure 3) . However, these differences were not present at the start of RRT. Patients with glomerulonephritis had significantly higher eGFR levels at their first visit to a PN than the other PRDs, but had to start RRT after a rapid decline in renal function. In contrast, patients with pyelonephritis had a significantly longer time between the first visit to a PN and start of RRT and together with those with cystic kidneys had a very slow rate of decline in renal function. Patients with an unknown PRD had a very short time between the first visit to a PN and start of RRT. Nearly 70% of those patients had to start RRT within 1 month after the first visit to a PN.
Discussion
In paediatric patients on RRT, large differences exist in the eGFR at the start of RRT. The main determinants of eGFR at start were age, gender, treatment modality at start as well as time between the first visit to a PN and start of RRT. We found slightly higher median eGFR levels at start compared with US dialysis patients [5, 12] and patients from the Eurotransplant registry [13] . However, these studies took place at an earlier period in slightly younger patients.
Age
Adolescent patients started with higher eGFR levels compared with children and infants. The same difference has been found in other studies [5, 12] , and it was consistent using different formulas like the Counahan and the new Schwartz. Treatment of infants is difficult and complicated, so physicians may wait longer before starting treatment, resulting in lower eGFR levels. It has been shown that infants can survive long periods without dialysis if they still have urine output [14] . Furthermore, infants frequently show spontaneous improvement in GFR during the first year of life, so physicians may delay treatment further to see if this occurs [14, 15] .
Gender
Males started with higher eGFR levels compared with females. Similar differences in eGFR between genders were also found in children in the United States Renal Data System and North American Pediatric Renal Transplant Cooperative study [5, 12] . The gender difference was present only during adolescent age. A possible explanation for this could be related to the use of different K values for adolescent males in the original Schwartz formula. The use of different formulas for males and females has been found appropriate in some studies [3, 9, 16] although not in others [17] [18] [19] . When we used a single K value as suggested in the revised Schwartz and Counahan formula, the gender differences disappeared. The issue that K values are appropriate in children approaching chronic kidney disease (CKD) stage V is not yet exhaustively addressed since appropriate validation studies are lacking. Such patients frequently have delayed puberty, so physicians may believe that it is inappropriate to use a different K value for males and females, resulting in an artificial difference. Nevertheless, gender differences have also been noted in adults, with men starting with higher median eGFRs than women, so the findings in children may be real [20] .
Treatment modality
Patients starting with a transplant had higher eGFR levels compared with patients starting on dialysis. The higher eGFR levels suggest that patients starting with a pre-emptive transplant start RRT earlier than dialysis patients. We hypothesize that patients who have a suitable donor are likely to have their transplant timed early enough to avoid dialysis [21] and therefore at a higher GFR than that at which they would commence dialysis. Nevertheless, a previous study found no differences in eGFR levels between pre-emptive and post-dialysis transplant patients [13] . However, their eGFR levels were much lower than those reported in our study. It is noteworthy that the median eGFR for adolescent patients starting with a transplant (15.8 mL/min/1.73 m 2 ) is higher than both the European and the KDOQI recommendations for consideration of RRT [1, 2] . However, specific transplantation guidelines such as the United Network for Organ Sharing suggest that patients can be put on the waiting list with higher eGFR levels of <20 mL/min/1.73 m 2 , possibly explaining these differences. Finally, as the variable policies and regulations with respect to (deceased donor) pre-emptive transplantation vary between countries, i.e. some countries do not offer pre-emptive deceased donor transplants [13] , and the accepted eGFR for listing may vary, this may have affected the overall GFR at pre-emptive transplantation.
Regions
We found small differences between regions in Europe with slightly higher eGFR levels in Eastern Europe. As we only had information from two relatively small Eastern European countries, this may not be representative for complete area and could be a chance finding due to small numbers. However, possible explanations for the difference may be diverse, including a different timing of the replacement of the Jaffe method by enzymatic measurements for the measurement of serum creatinine levels, therefore giving different eGFRs. Furthermore, referral of patients, pre-dialysis treatment, social, ethnic or economic backgrounds of the patients may be different, all possibly affecting the eGFR at start of RRT. All require further research to determine the exact cause.
First visit to a PN
The eGFR at the first visit to a PN was low; only 40% of patients had eGFR levels >20 mL/min/1.73 m 2 . However, we included only a very selective group of patients, namely those reaching RRT, and therefore the median eGFR at the first visit to a PN is not representative of all patients in predialysis care. This may explain the low eGFR level on the first visit to the PN. A third of the patients had to start RRT within a month after the first visit to a PN. This percentage is similar to the 21% reported in Polish paediatric dialysis patients [22] and to the rates seen in adults (15-35%) [23] .
We did not have information on whether the short time between the first visit and start of RRT was due to a late diagnosis or to a late referral, or possibly severe acute irreversible disease (e.g. an anti-neutrophil cytoplasmic autoantibody (ANCA) associated glomerulonephritis). Late referral in children has shown to be associated with a worse clinical status and worse chemical parameters [22] . Late diagnosis could be due to rapidly worsening renal function, but could also be explained by notoriously late recognition of renal disease. Further research is warranted to determine what fraction of paediatric patients could benefit from earlier referral, management by a specialist and access to nephroprotective treatment, slowing the decline in renal function and delaying the need for RRT [24] .
Decline in renal function
There was a difference in the rate of decline in eGFR in the period between the first visit to a PN and the start of RRT between the different PRDs. There seemed to be two patterns of decline in renal function. The first group, including patients with glomerulonephritis and hereditary nephropathy, presented with relatively high eGFR levels and started RRT after a rapid decline in eGFR. The second group, including patients with pyelonephritis and HUS, seemed to present with an already low eGFR and started RRT after a slow decline in eGFR. We could only present data on those patients who started RRT. As a consequence, we do not have information on those visiting the PN but not requiring RRT. Other studies have shown that ∼25% of paediatric patients with CKD will have to be treated with RRT at paediatric age [25] . This will have resulted in a bias in estimating the decline in eGFR. However, our data demonstrate what is happening in those children who require RRT.
Drawbacks
This study has some drawbacks. First, information regarding eGFR at the start was only available for 55% of the population in the different countries, resulting in a selection of the patients. It is possible that only certain centres reported data on their patients as the participation rate between countries differed, as did the participation rate for the different treatment modalities.
Second, eGFR values were calculated using the Schwartz formulae. Recent papers have suggested that the Schwartz formula can overestimate eGFR levels and that the precision is poor [19, 26] . The overestimation of GFR has been attributed to the change in creatinine measurement methods since the development of the original formula. We would have preferred to obtain direct GFR measurements such as iothalamate, iohexol or the mean urinary clearance of creatinine and urea at time of RRT initiation. However, these procedures are not common practice in many of the sites reporting to the registry and would have allowed the study of much fewer patients than the estimation of GFR from serum creatinine and height. Also, the 'old' Schwartz formula is the most widely used estimate of GFR and recommended by the guidelines. Furthermore, differences between groups, besides differences between genders, were very similar when applying the Counahan or new Schwartz formula, except that the eGFR levels were lower. Still, different centres may have applied different formulae, possibly affecting the timing of the start of RRT. Finally, in recent years, there has been a transition from the Jaffe to enzymatic methods to determine serum creatinine levels. Still, no increase in eGFR over the reporting years was observed. Also, while the methodological transition could have affected absolute eGFR levels, it would have applied randomly to the different subgroups studied, with the exception of differences between countries.
In conclusion, the main determinants of the timing of start of RRT were age, gender, treatment modality at start, and the time between the first visit to a PN and start of RRT. Future studies are needed to evaluate the impact of the decision of when to start RRT in the individual patient and to evaluate the impact on outcome measures such as nutritional status, growth, the incidence of complications and the rate of hospitalization.
